Physician profile
Allison Kinder
NPI 1043655210
$880.55
in general payments reported to CMS, 2019-2025
20 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $370 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $126.77 | 2024 | |
| Eisai INC. | $125.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $93.35 | 2024-2025 | Breztri, Tezspire |
| Neurocrine Biosciences, INC. | $89.90 | 2024-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.97 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $42.26 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $39.97 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $37.93 | 2025 | Rexulti |
| Dexcom, INC. | $36.85 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $36.45 | 2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.81 | 2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $31.13 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $21.66 | 2025 | Qelbree |
| Almatica Pharma LLC | $19.44 | 2025 | Loreev Xr |
| Amgen INC. | $18.73 | 2025 | Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.51 | 2025 | Auvelity |
| Exact Sciences Corporation | $15.97 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.76 | 2025 | Gardasil 9, Capvaxive |
| Lundbeck LLC | $14.08 | 2025 | Rexulti |
| Abbvie INC. | $14.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Kinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.